Nokia Oyj (PRA:NOKIA)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions CZK. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	462,369	579,971	417,445	584,004	783,132	465,773
Market Cap Growth	19.56%	38.93%	-28.52%	-25.43%	68.14%	-1.04%
Enterprise Value	428,926	477,995	391,632	493,703	697,362	436,781
Last Close Price	88.26	101.08	68.92	98.39	123.62	76.26
PE Ratio	18.34	18.02	25.41	5.69	19.39	-
PS Ratio	0.97	1.20	0.80	1.02	1.42	0.81
PB Ratio	0.94	1.11	0.82	1.13	1.80	1.41
P/TBV Ratio	1.54	1.63	1.21	1.68	3.05	3.26
P/FCF Ratio	12.63	11.39	25.41	27.69	15.24	13.86
P/OCF Ratio	9.19	9.23	12.83	16.40	11.99	10.08
EV/Sales Ratio	0.91	0.99	0.75	0.86	1.26	0.76
EV/EBITDA Ratio	6.71	6.39	5.53	5.32	10.47	8.64
EV/EBIT Ratio	11.15	8.71	7.95	7.56	15.61	16.37
EV/FCF Ratio	11.72	9.39	23.84	23.41	13.57	12.99
Debt / Equity Ratio	0.21	0.23	0.25	0.26	0.32	0.52
Debt / EBITDA Ratio	1.59	1.49	1.69	1.46	1.96	3.02
Debt / FCF Ratio	2.77	2.36	7.84	6.44	2.74	5.07
Asset Turnover	0.51	0.49	0.51	0.57	0.58	0.58
Inventory Turnover	4.27	4.18	4.16	4.80	5.77	5.28
Quick Ratio	1.15	1.34	1.37	1.27	1.39	1.34
Current Ratio	1.46	1.58	1.66	1.59	1.62	1.55
Return on Equity (ROE)	4.47%	8.27%	3.09%	21.61%	11.02%	-17.98%
Return on Assets (ROA)	2.59%	3.44%	3.01%	4.07%	2.94%	1.69%
Return on Capital (ROIC)	3.91%	5.30%	4.71%	6.74%	5.32%	3.20%
Return on Capital Employed (ROCE)	5.90%	7.80%	6.90%	9.00%	6.40%	4.20%
Earnings Yield	5.45%	5.55%	3.94%	17.58%	5.16%	-14.22%
FCF Yield	7.92%	8.78%	3.94%	3.61%	6.56%	7.22%
Dividend Yield	3.96%	3.49%	4.66%	2.95%	1.61%	-
Payout Ratio	76.16%	55.91%	91.88%	7.91%	0.56%	-
Buyback Yield / Dilution	0.20%	-0.05%	2.07%	0.31%	-1.28%	0.25%
Total Shareholder Return	4.02%	3.44%	6.73%	3.26%	0.33%	0.25%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.